Drug Profile
Upadacitinib - AbbVie
Alternative Names: ABT-494; RINVOQ; Upadacitinib extended release - Abbvie; Upadacitinib modified release - Abbvie; Upadacitinib prolonged release - Abbvie; Upadacitinib tartrate; Upadicitinib hemihydrate - AbbvieLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Registered Non-radiographic axial spondyloarthritis
- Phase III Alopecia areata; Giant cell arteritis; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Systemic lupus erythematosus; Vasculitis; Vitiligo
Most Recent Events
- 05 Feb 2024 Takeda plans a phase III VICTRIVA trial for Crohn's Disease (Combination therapy, Treatment-experienced) in July 2024 (PO) (NCT06227910)
- 15 Dec 2023 Phase-III clinical trials in Vitiligo (In adolescents, In adults) in USA (PO) (NCT06118411)
- 10 Nov 2023 Efficacy data from phase III SELECT-PsA 1trial in Psoriatic arthritis presented at the ACR Convergence 2023 (ACR-ARP-2023)